Platin ve Bakır Temelli N-Heterosiklik Karben (NHC) Komplekslerinin Antikanser Özellikleri ve Etki Mekanizmaları

Metal-N-heterosiklik karben (M-NHC) kompleksleri uzun yıllardır organometalik kimyada katalitik aktivitegösteren bileşikler olarak ön plana çıkmaktadırlar. Son yıllarda bu bileşiklerin biyolojik özelliklerini ön planaçıkaran çalışmalar yoğun ilgi görmektedir. Kanser çağımızın önemli bir hastalığı olup tedavisinde kullanılacakilaçların keşfi oldukça önemlidir. Bu nedenle M-NHC komplekslerinin antikanser özellikleri ile ilgili çalışmalarönem kazanmıştır. Antikanser etki gösteren platin ve bakır temelli M-NHC kompleksleri, bu komplekslerin enönemli olanlarındandır. NHC’lere bağlı bulunan sübstitüentlerin değiştirilmesi ile M-NHC komplekslerininantikanser aktiviteleride değişmektedir. Bu bileşiklerin antikanser etki mekanizmaları DNA mutasyonları veReaktif Oksijen Türleri (ROT)‘nden oluşur. Bununla beraber M-NHC komplekslerinin antikanser etkimekanizmalarını tam olarak ortaya koyacak ve yeni sentezlenecek komplekslere yol gösterecek çalışmalara ihtiyaçvardır.

Platinum and Copper Based N-Heterocyclic Carbene (NHC) Complexes as Anticancer Properties and Mechanisms of Effect

Metal-NHC (M-NHC) complexes have been used as the compounds that show catalytic activity for organometallic chemistry at a long time. In recent years, the studies that emphasize the biological properties of these compounds have attracted great interest. Cancer is an important disease of our age and the discovery of drugs to be used in its treatment is very important. Therefore, studies on anticancer properties of M-NHC complexes have important. Platinum and copper-based M-NHC complexes that show the anti-carcinogenic effect are the most important of these complexes. Furthermore, changing of the substituents attached to NHCs changes the anti-carcinogenic activities of the M-NHC complexes. The anti-carcinogenic mechanisms of these compounds occur from DNA mutation and Reactive Oxygen Species (ROS). Also, there is a need for studies that will fully reveal the anticancer action mechanisms of M-NHC complexes and lead to new complexes to be synthesized.

PDF

___

[1] Öfele K. 1968. 1,3-Dimethyl-4-imidazolinyliden-(2)-pentacarbonylchrom ein neuer Übergangsmetall-carben-komplex. Journal Organometallic Chemistry, 12: 42-43.
[2] Matzingerand S., Fulscher M.P. 1995. Methyl substitution in carbenes. A theoretica prediction of the singlet-triplet energy separation of dimethylcarbene. Journal of Physical Chemistry, 99 (27): 10747-10751
[3] Wanzlick H.W., Schönherr H.J. 1968. Direct Synthesis of a Mercury Salt-Carbene Complex. Angewandte Chemie International Edition, 7 (2): 141-142.
[4] Arduengo III A.J., Harlow R.L., Kline M. 1991. A Stable Crystalline Carbene. Journal of the American Chemical society,113(1): 361-363.
[5] Sarı Y., Aktaş A., Barut Celepci D., Gök Y., Aygün M. 2017. Synthesis, Characterization and Crystal Structure of New 2-Morpholinoethyl-Substituted Bis-(NHC)Pd(II) Complexes and the Catalytic Activity in the Direct Arylation Reaction. Catalysis Letter, 147 (9): 2340-2351.
[6] Gök Y., Aktaş A., Erdoğan H., Sarı Y. 2018. New 4-vinylbenzyl-substituted bis(NHC)-Pd(II) complexes: Synthesis, characterization and the catalytic activity in the direct arylation reaction. Inorganica Chimica Acta, 471: 735-740.
[7] Erdoğan H., Aktaş A., Gök Y., Sarı Y. 2018. N-Propylphthalimide-substituted bis-(NHC)PdX2 complexes: synthesis, characterization and catalytic activity in direct arylation reactions. Transition Metal Chemistry, 43 (1): 31-37.
[8] Aktaş A., Akkoç S., Gök Y. 2013. Palladium catalyzed Mizoroki–Heck and Suzuki–Miyaura reactions using naphthalenomethyl-substituted imidazolidin-2-ylidene ligands in aqueous media. Journal of Coordination Chemistry, 66 (16): 2901-2909.
[9] Haque R.A., Choo S.Y., Budagumpi S., Iqbal M.A., Abdullah A.A. 2015. Silver(I) complexes of mono- and bidentate N-heterocyclic carbene ligands: Synthesis, crystal structures, and in vitro antibacterial and anticancer studies. European Journal of Medicinal Chemistry, 90: 82-92.
[10] Li Y., Tan C.-P., Zhang W., He L., Ji L.-N., Mao Z.-W. 2015. Phosphorescent iridium(III)-bisN-heterocyclic carbene complexes as mitochondria-targeted theranostic and photodynamic anticancer agents. Biomaterials 39: 95-104.
[11] Nguyen M.T., Nguyenand T.L., Le H.T. 1999. Theoretical Study of Dithioformic Acid, Dithiohydroxy Carbene and Their Radica Cations: Unimolecularand Assisted Rearrangements. The Journal of Physical Chemistry A, 103 (29): 5758-5765.
[12] Kühl O. 2010. Functionalised N-Heterocyclic Carbene Complexes. John Wiley&Sons, 7-8.
[13] Kühl O. 2009. Sterically induced differences in N-heterocyclic carbene transition metal complexes. Coordination Chemistry Reviews, 253 (21-22): 2481-2492.
[14] Cisnetti F., Gautier A. 2013. Metal/N-Heterocyclic Carbene Complexes: Opportunities for the Development of Anticancer Metallodrugs. Angewandte Chemie International Edition, 52 (46): 11976-11978.
[15] Aktaş A., Keleştemur Ü., Gök Y., Balcıoğlu S., Ateş B., Aygün M. 2017. Synthesis, characterization, crystal structure, and antimicrobial studies of 2-morpholinoethyl-substituted benzimidazolium salts and their silver(I)-N-heterocyclic carbene complexes. Research on Chemical Intermediates, 43 (11): 6379–6393.
[16] Savić N.D., Glišić B.Đ., Wadepohl H., Pavic A., Senerovic L., Nikodinovic-Runic J., Djurana M.I. 2016. Silver(I) complexes with quinazoline and phthalazine: synthesis, structural characterization and evaluation of biological activities. Medicinal Chemistry Communication, 7: 282-291.
[17] Krishnamoorthy P., Sathyadevi P., Butorac R.R., Cowley A.H., Bhuvanesh N.S.P., Dharmaraj N. 2012. Copper(I) and nickel(II) complexes with 1[thin space (1/6-em)]:[thin space (1/6-em)]1 vs. 1[thin space (1/6-em)]:[thin space (1/6-em)]2 coordination of ferrocenyl hydrazone ligands: Do the geometry and composition of complexes affect DNA binding/cleavage, protein binding, antioxidant and cytotoxic activities, Dalton Transactions, 41: 4423-4436.
[18] Li Y., Liu G.-F., Tan C.-P., Ji L.-N., Mao Z.-W. 2014. Antitumor properties and mechanisms of mitochondria-targeted Ag(I) and Au(I) complexes containing N-heterocyclic carbenes derived from cyclophanes. Metallomics, 6: 1460-1468.
[19] Çetinkaya B., Özdemir İ., Binbaştoğlu B., Günal S. 1999. Antibacterial and Antifungal Activities of Complexes of Ruthenium (II). Arzneimitteforschung, 49 (6): 538-540.
[20] Aktaş A., Taslimi P., Gülçin İ., Gök Y. 2017. Novel NHC Precursors: Synthesis, Characterization, and Carbonic Anhydrase and Acetylcholinesterase Inhibitory Properties. Archiv der Pharmazie, 350, DOI:10.1002/ardp.201700045.
[21] Sarı Y., Aktaş A., Taslimi P., Gök Y., Gülçin İ. 2017. Novel N-propylphthalimide and 4- vinylbenzyl-substituted benzimidazole salts: Synthesis, characterization, and determination of their metal chelating effects and inhibition profiles against acetylcholinesterase and carbonic anhydrase enzymes. Journal of Biochemical and Molecular Toxicology, doi.org/10.1002/jbt.22009.
[22] Erdemir F., Barut Celepci D., Aktaş A., Taslimi P., Gök Y., Karabıyık H., Gülçin İ. 2018. 2- Hydroxyethyl substituted NHC precursors: Synthesis, characterization, crystal structure and carbonic anhydrase, α-glycosidase, butyrylcholinesterase, and acetylcholinesterase inhibitory properties. Journal of Molecular Structure 1155: 797-806.
[23] Türker F., Barut Celepci D., Aktaş A., Taslimi P., Gök Y., Aygün M., Gülçin İ. 2018. metacyanobenzyl substituted benzimidazolium salts: Synthesis, characterization, crystal structure and carbonic anhydrase, α-glycosidase, butyrylcholinesterase, and acetylcholinesterase inhibitory properties. Archiv der Pharmazie, doi.org/10.1002/ardp.201800029.
[24] Behçet A., Çağlılar T., Barut Celepci D., Aktaş A., Taslimi P., Gök Y., Aygün M., Kaya R., Gülçin İ. 2018. Synthesis, characterization and crystal structure of 2-(4-hydroxyphenyl)ethyl and 2-(4-nitrophenyl)ethyl Substituted Benzimidazole Bromide Salts: Their inhibitory properties against carbonic anhydrase and acetylcholinesterase. Journal of Molecular Structure, 1170: 160- 169.
[25] Rosenberg B., VanCamp L., Krigas T. 1965. Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode. Nature, 205: 698-699.
[26] Ott I., Gust R. 2007. Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment. Anti-Cancer Agents in Medicinal Chemistry, 7 (16): 95-110.
[27] Gust R., Beck W., Jaouen G., Schönenberger H. 2009. Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases: Part 2: Use of non-steroidal ligands. Coordination Chemistry Reviews, 253 (21-22): 2760-2779.
[28] Berners-Price S.J. 2011. Activating Platinum Anticancer Complexes with Visible Light. Angewandte Chemie International Edition, 50 (4): 804-805.
[29] Wedlock L.E., Berners-Price S.J. 2011. Recent Advances in Mapping the Sub-cellular Distribution of Metal-Based Anticancer Drugs. Australian Journal of Chemistry, 64 (6): 692-704.
[30] Wheate N.J., Walker S., Craig G.E., Oun R. 2010. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Transactions, 39: 8113-8127.
[31] Monneret C. 2011. Platinum anticancer drugs. From serendipity to rational design. Annales Pharmaceutiques Françaises, 69 (6): 286-295.
[32] Rabik C.A. Dolan ME. 2007. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews, 33 (1): 9-23.
[33] Gust R., Beck W., Jaouen G., Schönenberger H. 2009. Optimization of cisplatin for the treatment of hormone dependent tumoral diseases: Part 1: Use of steroidal ligands. Coordination Chemistry Reviews, 253 (21-22): 2742-2759.
[34] Tan S.J. Yan Y.K., Lee P.P., Lim K.H. 2010. Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Medicinal Chemistry, 2 (10): 1591-1608.
[35] Scott L.E., Orvig C. 2009. Medicinal Inorganic Chemistry Approaches to Passivation and Removal of Aberrant Metal Ions in Disease. Chemical Reviewes, 109 (10): 4885-4910.
[36] Hindi K.M., Panzner M.J., Tessier C.A., Cannon C.L., Youngs W.J. 2009. The Medicinal Applications of Imidazolium Carbene−Metal Complexes. Chem. Rev., 109 (8): 3859-3884.
[37] Gautier A., Cisnetti F. 2012. Advances in metal–carbene complexes as potent anti-cancer agents. Metallomics, 4: 23-32.
[38] Mercs L., Albrecht M. 2010. Beyond catalysis: N-heterocyclic carbene complexes as components for medicinal, luminescent, and functional materials applications. Chemical Society Reviews, 39 (6): 1903-1912.
[39] Liu W., Gust R. 2013. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chemical Society Reviews, 42 (2): 755-773.
[40] Alves G., Morel L., El-Ghozzi M., Avignant D., Legeret B., Nauton L., Cisnetti F., Gautier A. 2011. A platinum Chugaev carbene complex as a potent anticancer agent. Chemical Communications, 47 (27): 7830-7832.
[41] Sun R.W.-Y., Chow A.L.-F., Li X.-H., Yan J.J., Chui S.S.-Y., Che C.-M. 2011. Luminescent cyclometalated platinum(II) complexes containing N-heterocyclic carbene ligands with potent in vitro and in vivo anti-cancer properties accumulate in cytoplasmic structures of cancer cells, Chemical Science, 2: 728-736.
[42] Bouché M., Dahm G., Wantz M., Fournel S., Acharda T., Bellemin-Laponnaz S. 2016. Platinum(IV) N-heterocyclic carbene complexes: their synthesis, characterisation and cytotoxic activity. Dalton Transactions, 45 (28): 11362-11368.
[43] Ramiro-Cortés Y., Guemez-Gamboa A., Morán J. 2011. Reactive oxygen species participate in the p38-mediated apoptosis induced by potassium deprivation and staurosporine in cerebellar granule neurons. International Journal of Biochemistry & Cell Biology, 43 (9): 1373-1382.
[44] Rehm T., Rothemund M., Muenzner J.K., Noor A., Kempe R., Schobert R. 2016 Dalton Trans., 45: 15390-15398
[45] Sergent C., Franco N., Chapusot C., Lizard-Nacol S., Isambert N., Correia M., Chauffert B. 2002. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemotherapy and Pharmacology, 49 (6): 445-452.
[46] Shen D.-W., Cardarelli Hwang C.J., Cornwell M., Richert N., Ishii S., Pastan I., Gottesman M.M. 1986. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. Journal of Biological Chemistry, 261: 7762-7770.
[47] Chekkat N., Dahm G., Chardon E., Wantz M., Sitz J., Decossas M., Lambert O., Frisch B., Rubbiani R., Gasser G., Guichard G., Fournel S., Bellemin-Laponnaz S. 2016. N-Heterocyclic Carbene–Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy. Bioconjugate Chemistry, 27 (8): 1942-194.
[48] Tisato F., Marzano C., Porchia M., Pellei M., Santini C. 2010. Copper in diseases and treatments, and copper-based anticancer strategies. Medicinal Research Reviews, 30 (4): 708-749.
[49] Wang T., Guo Z. 2006. Copper in Medicine: Homeostasis, Chelation Therapy and Antitumor Drug Design. Current Medicinal Chemistry, 13 (5): 525-537.
[50] Marzano C., Pellei M., Tisato F., Santini C. 2009. Anti-Cancer Agents. Medicinal Chemistry, 9 (2): 185-211.
[51] Teyssot M.L., Jarrousse A.S., Chevry A., De Haze A., Beaudoin C., Manin M., Nolan S.P., DiezGonzalez S., Morel L., Gautier A. 2009. Toxicity of Copper(I)–NHC Complexes Against Human Tumor Cells: Induction of Cell Cycle Arrest, Apoptosis, and DNA Cleavage. Chemistry A European Journal, 15 (2): 314-318.
[52] Ruiz-Azuara L., Bravo-Gomez M.E. 2010. Copper Compounds in Cancer Chemotherapy. Current Medicinal Chemistry, 17 (31): 3606-3615.
[53] Bowen R.J., Navarro M., Shearwood A.M., Healy P.C., Skelton B.W., Filipovska A., BernersPrice S.J. 2009. 1:2 Adducts of copper(I) halides with 1,2-bis(di-2-pyridylphosphino)ethane: solid state and solution structural studies and antitumour activity. Dalton Transactions, 2009 (48): 10861-10870.
[54] Teyssot M.L., Jarrousse A.S., Manin M., Chevry A., Roche S., Norre F., Beaudoin C., Morel L., Boyer D., Mahiou R., Gautier A. 2009. Metal-NHC complexes: a survey of anti-cancer properties. Dalton Transactions, 2009 (35): 6894-6902.
[55] Pellei M., Gandin V., Marinelli M., Marzano C., Yousufuddin M., Dias H.V.R., Santini C. 2012. Synthesis and Biological Activity of Ester- and Amide-Functionalized Imidazolium Salts and Related Water-Soluble Coinage Metal N-Heterocyclic Carbene Complexes. Inorganic Chemistry, 51 (12): 9873-9882.
[56] Yang P., Guo M. 1999. Interactions of organometallic anticancer agents with nucleotides and DNA. Coordination Chemistry Reviews, 185–186: 189-211.
[57] Bertrand B., Romanov A.S., Brooks M., Davis J., Schmidt C., Ott I., O’Connell M., Bochmann M. 2017. Synthesis, structure and cytotoxicity of cyclic (alkyl)(amino) carbene and acyclic carbene complexes of group 11 metals. Dalton Transactions, 46: 15875-15887.
[58] Streciwilk W., Hackenberg F., Muller-Bunz H., Tacke M. 2014. Synthesis and cytotoxicity studies of p-benzyl substituted NHC–copper(I) bromide derivatives. Polyhedron, 80: 3–9.
[59] Walther W., Fichtner I., Hackenberg F., Streciwilk W., Tacke M. 2014. In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR. Letters in Drug Design & Discovery, 11 (2):825-832.
[60] Pellei M., Gandin V., Marinelli M., Orsetti A., Del Bello F., Santini C., Marzano C. 2015. Novel triazolium based 11th group NHCs: synthesis, characterization and cellular response mechanisms. Dalton Transactions, 44: 21041-21052.
[61] Pizarro A.M., Sadler P.J. 2009. Unusual DNA binding modes for metal anticancer complexes. Biochimie, 91 (10): 1198-1211.
[62] Ehrenfeld G.M., Shipley J.B., Heimbrook D.C., Sugiyama H., Long E.C., Van B.J.H., Van M.G.A., Oppenheimer N.J., Hecht S.M. 1987. Copper-Dependent Cleavage of DNA by Bleomycin. Biochemistry, 26: 931-942.